Document Detail


Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
MedLine Citation:
PMID:  20456300     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Hispanic-Americans are a rapidly growing population in the United States, yet gastro-oesophageal reflux disease (GERD) is not well studied in this population.
AIM: To compare the efficacy of esomeprazole, lansoprazole and pantoprazole in suppressing gastric acid, including the area of the 'acid pocket,' in Hispanics with GERD.
METHODS: In this open-label, 3-way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5-7-day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10-17-day washout periods. Intragastric pH was measured for 24 h using dual probes with a distal and proximal (area of the 'acid pocket') electrode.
RESULTS: Esomeprazole suppressed intragastric acid (pH >4.0) significantly longer over 24 h (primary end point) compared with lansoprazole and pantoprazole (P < 0.0001), and proximal gastric acid (pH >4.0) significantly longer over 24 h compared with lansoprazole (P < 0.05) and pantoprazole (P < 0.0001).
CONCLUSIONS: Esomeprazole was more effective than lansoprazole and pantoprazole in suppressing gastric acidity at both intragastric distal and proximal (area of the acid pocket) sites in Hispanics with GERD. Future studies are warranted to understand better the role of the acid pocket in GERD (Clinical trial numbers: D9612L00106; ClinicalTrials.gov: NCT00410592).
Authors:
D Morgan; J Pandolfino; P O Katz; J L Goldstein; P N Barker; M Illueca
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-04-23
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  32     ISSN:  1365-2036     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-19     Completed Date:  2011-06-17     Revised Date:  2013-06-04    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  200-8     Citation Subset:  IM    
Affiliation:
University of North Carolina School of Medicine, Chapel Hill, NC 27599-7080, USA. douglas_morgan@med.unc.edu
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00410592
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage*
Adolescent
Adult
Aged
Anti-Ulcer Agents / administration & dosage*
Cross-Over Studies
Drug Therapy, Combination
Esomeprazole Sodium / administration & dosage*
Female
Gastric Acid / secretion
Gastroesophageal Reflux / drug therapy*
Hispanic Americans*
Humans
Male
Middle Aged
Patient Compliance
Treatment Outcome
United States
Young Adult
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103577-45-3/lansoprazole; D8TST4O562/pantoprazole; L2C9GWQ43H/Esomeprazole Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  drr-2 encodes an eIF4H that acts downstream of TOR in diet-restriction-induced longevity of C. elega...
Next Document:  Body mass index, chronic atrophic gastritis and heartburn: a population-based study among 8936 older...